1810-P: Triple Combination Therapy of GLP-1 Receptor Agonist Semaglutide with an FXR Agonist and AC Inhibitor Reverses Nonalcoholic Steatohepatitis (NASH) in Diet-Induced and Biopsy-Confirmed Mice

非酒精性脂肪性肝炎 赛马鲁肽 兴奋剂 内科学 医学 内分泌学 脂肪肝 甘油三酯 非酒精性脂肪肝 脂肪变性 受体 2型糖尿病 利拉鲁肽 胆固醇 糖尿病 疾病
作者
Jenny Norlin,Diego A. Miranda,Jamie Geier Bates,Nora Elisabeth Zois,Sanne Skovgård Veidal,Michael Feigh,James L. Trevaskis,Markus Robert Latta
出处
期刊:Diabetes [American Diabetes Association]
卷期号:69 (Supplement_1) 被引量:1
标识
DOI:10.2337/db20-1810-p
摘要

Semaglutide (SEMA), FXR agonists and ACC inhibitors are under active clinical investigation for the treatment of NASH. Here, we explored whether the effects of SEMA (0.12 mg/kg, s.c., q.d.) on NASH endpoints could be enhanced by addition of an FXR agonist (cilofexor, CILO; 30 mg/kg) and/or an acetyl-CoA carboxylase inhibitor (firsocostat analogue, ACCi; 5 mg/kg, both p.o., q.d.) in the AMLN diet-induced and biopsy-confirmed DIO-NASH mouse (n=15-16/group). After 12 weeks of treatment, SEMA and triple therapy reduced body weight 18%, being slightly enhanced in the double combination of SEMA+CILO (21%). Liver triglyceride concentration was reduced by SEMA (by 38% vs. vehicle, p<0.001). Addition of CILO or ACCi or both to SEMA further reduced liver lipid by 64%, 73% and 81%, respectively (all p<0.001 vs. SEMA). Histopathological pre-to-post NAFLD activity score (NAS) was reduced in 3/16 (19%) of vehicle controls and in all mice (100%) treated with SEMA or triple therapy. Further, the number of mice that exhibited a 3+ point improvement in NAS was improved with the triple combination (12/16; 75%) vs. SEMA alone (2/16, 13%). Likewise, the triple combination caused the greatest improvements in fibrosis stage pre-to-post (7/16, 44%, improved; 1/16 worsened), followed by the SEMA-treated group (6/16, 38% improved; 0/16 worsened) relative to vehicle (2/16, 13% improved; 7/16, 44% worsened). Collagen-1a and a-SMA immunoreactivity (% area) tended to be or were significantly improved with SEMA (4.2%; n.s., and 1.4%; p<0.001) and triple therapy (3.9%; p<0.045 and 0.9% p<0.001) vs. vehicle (6.3% and 4.6%). SEMA significantly improved NAS and fibrosis endpoints. While addition of either single agent improved liver fat reduction, triple therapy improved pre-to-post NAS and fibrosis stage relative to SEMA alone in DIO-NASH mice. These data support development of combination approaches for NASH. Disclosure J. Norlin: Employee; Self; Novo Nordisk A/S. Stock/Shareholder; Self; Novo Nordisk A/S. D.A. Miranda: None. J.G. Bates: Employee; Self; Gilead Sciences, Inc. N.E. Zois: Employee; Self; Gubra. S. Veidal: None. M. Feigh: None. J.L. Trevaskis: Employee; Self; Gilead Sciences, Inc. M. Latta: Employee; Self; Novo Nordisk A/S.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
王知颖发布了新的文献求助10
1秒前
monster发布了新的文献求助10
2秒前
dd完成签到,获得积分10
2秒前
2秒前
想看雪的人完成签到 ,获得积分10
3秒前
4秒前
yang完成签到,获得积分10
4秒前
楠楠发布了新的文献求助10
4秒前
4秒前
4秒前
5秒前
nwy关闭了nwy的文献求助
5秒前
5秒前
充电宝的应助被mwx采纳,获得10
5秒前
sukiii发布了新的文献求助10
6秒前
8秒前
10秒前
molihuakai的应助被322采纳,获得10
10秒前
罗战菊完成签到 ,获得积分10
11秒前
11秒前
wxqz完成签到,获得积分20
11秒前
大气幻柏发布了新的文献求助10
11秒前
12秒前
CipherSage的应助被土豆采纳,获得10
13秒前
打打的应助被啦啦啦采纳,获得10
13秒前
djuanyx完成签到,获得积分10
13秒前
13秒前
葡萄完成签到,获得积分10
13秒前
haung完成签到,获得积分10
13秒前
510完成签到,获得积分10
14秒前
王知颖发布了新的文献求助10
15秒前
wxqz发布了新的文献求助10
15秒前
15秒前
15秒前
Lucas的应助被胖头鱼采纳,获得50
16秒前
17秒前
19秒前
皮卡丘发布了新的文献求助10
19秒前
艾格的应助被风吹麦浪采纳,获得10
20秒前
322完成签到,获得积分10
20秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8188118
求助须知:如何正确求助?哪些是违规求助? 9575977
关于积分的说明 21844428
捐赠科研通 7785918
什么是DOI,文献DOI怎么找? 3435205
关于科研通互助平台的介绍 2559558
邀请新用户注册赠送积分活动 2482065